HUTCHMED (China) Limited NASDAQ:HCM

HUTCHMED (China) Limited stock price today

$16.21
+1.94
+13.59%
Financial Health
0
1
2
3
4
5
6
7
8
9

HUTCHMED (China) Limited stock price monthly change

-26.44%
month

HUTCHMED (China) Limited stock price quarterly change

-26.44%
quarter

HUTCHMED (China) Limited stock price yearly change

-18.50%
year

HUTCHMED (China) Limited key metrics

Market Cap
2.46B
Enterprise value
1.95B
P/E
-6.13
EV/Sales
7.14
EV/EBITDA
-11.59
Price/Sales
8.20
Price/Book
3.67
PEG ratio
0.08
EPS
0.65
Revenue
1.26B
EBITDA
37.95M
Income
149.70M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-63.69%
Oper. margin
-91.03%
Gross margin
1.74%
EBIT margin
-91.03%
EBITDA margin
3%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

HUTCHMED (China) Limited stock price history

HUTCHMED (China) Limited stock forecast

HUTCHMED (China) Limited financial statements

HUTCHMED (China) Limited (NASDAQ:HCM): Profit margin
Mar 2023 266.43M 84.27M 31.63%
Jun 2023 532.87M 168.55M 31.63%
Sep 2023 152.56M -33.88M -22.21%
Dec 2023 311.70M -69.23M -22.21%
HUTCHMED (China) Limited (NASDAQ:HCM): Analyst Estimates
Sep 2025 80.92M -305.20M -377.15%
Dec 2025 90.66M -288.14M -317.82%
Mar 2026 175.22M -869.42M -496.19%
Jun 2026 210.04M -1.04B -497.13%
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
HUTCHMED (China) Limited (NASDAQ:HCM): Payout ratio
Payout ratio 0%
HUTCHMED (China) Limited (NASDAQ:HCM): Dividend Yield
2019
2020
2021 0.36%
2022 0.7%
2023
HUTCHMED (China) Limited (NASDAQ:HCM): Debt to assets
Feb 2023 1297497000 497.48M 38.34%
Jun 2023 1297497000 497.48M 38.34%
Sep 2023 1279773000 536.38M 41.91%
Dec 2023 1279773000 536.38M 41.91%
HUTCHMED (China) Limited (NASDAQ:HCM): Cash Flow
Mar 2023 113.20M -157.97M 2.91M
Jun 2023 250.25M -339.81M 5.83M
Sep 2023 -3.57M 12.41M 21.41M
Dec 2023 -26.27M 42.39M 43.87M

HUTCHMED (China) Limited alternative data

HUTCHMED (China) Limited (NASDAQ:HCM): Employee count
Aug 2023 1,280
Sep 2023 1,990
Oct 2023 1,990
Nov 2023 1,990
Dec 2023 1,990
Jan 2024 1,990
Feb 2024 1,990
Mar 2024 1,988
Apr 2024 1,988
May 2024 1,988
Jun 2024 1,988
Jul 2024 1,988

HUTCHMED (China) Limited other data

1.97% -1.29%
of HCM is owned by hedge funds
16.64M -11.00M
shares is hold by hedge funds
Insider Compensation
Mr. Christian Hogg B.Sc., BSc, M.B.A., MBA (1966) Chief Executive Officer & Executive Director
$1,410,000
Dr. Weiguo Su B.Sc., Ph.D. (1957) Chief Scientific Officer, Executive Vice President & Executive Director
$1,210,000
Mr. Johnny Cheng C.A., BEc, CA (1967) Chief Financial Officer & Executive Director
$788,960
Mr. Chi Keung To ACGI, B.Sc., M.B.A. (1952) Executive Chairman
$80,000
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito (1952) Company Sec. & Non-Executive Director
$70,000
Wednesday, 25 December 2024
seekingalpha.com
Monday, 23 December 2024
globenewswire.com
Thursday, 19 December 2024
globenewswire.com
Friday, 13 December 2024
globenewswire.com
Thursday, 12 December 2024
globenewswire.com
Wednesday, 11 December 2024
globenewswire.com
Thursday, 5 December 2024
globenewswire.com
Tuesday, 3 December 2024
prnewswire.com
globenewswire.com
Thursday, 28 November 2024
globenewswire.com
Thursday, 21 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
globenewswire.com
Friday, 8 November 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Thursday, 17 October 2024
globenewswire.com
Wednesday, 16 October 2024
globenewswire.com
Wednesday, 2 October 2024
gurufocus.com
Friday, 27 September 2024
globenewswire.com
Tuesday, 24 September 2024
globenewswire.com
Thursday, 19 September 2024
businesswire.com
Tuesday, 17 September 2024
businesswire.com
Sunday, 8 September 2024
globenewswire.com
Friday, 30 August 2024
globenewswire.com
Wednesday, 21 August 2024
globenewswire.com
Thursday, 15 August 2024
globenewswire.com
Wednesday, 14 August 2024
benzinga.com
Friday, 9 August 2024
seekingalpha.com
Wednesday, 31 July 2024
seekingalpha.com
  • What's the price of HUTCHMED (China) Limited stock today?

    One share of HUTCHMED (China) Limited stock can currently be purchased for approximately $16.21.

  • When is HUTCHMED (China) Limited's next earnings date?

    Unfortunately, HUTCHMED (China) Limited's (HCM) next earnings date is currently unknown.

  • Does HUTCHMED (China) Limited pay dividends?

    No, HUTCHMED (China) Limited does not pay dividends.

  • How much money does HUTCHMED (China) Limited make?

    HUTCHMED (China) Limited has a market capitalization of 2.46B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 96.52% to 838M US dollars.

  • What is HUTCHMED (China) Limited's stock symbol?

    HUTCHMED (China) Limited is traded on the NASDAQ under the ticker symbol "HCM".

  • What is HUTCHMED (China) Limited's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of HUTCHMED (China) Limited?

    Shares of HUTCHMED (China) Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are HUTCHMED (China) Limited's key executives?

    HUTCHMED (China) Limited's management team includes the following people:

    • Mr. Christian Hogg B.Sc., BSc, M.B.A., MBA Chief Executive Officer & Executive Director(age: 59, pay: $1,410,000)
    • Dr. Weiguo Su B.Sc., Ph.D. Chief Scientific Officer, Executive Vice President & Executive Director(age: 68, pay: $1,210,000)
    • Mr. Johnny Cheng C.A., BEc, CA Chief Financial Officer & Executive Director(age: 58, pay: $788,960)
    • Mr. Chi Keung To ACGI, B.Sc., M.B.A. Executive Chairman(age: 73, pay: $80,000)
    • Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito Company Sec. & Non-Executive Director(age: 73, pay: $70,000)
  • How many employees does HUTCHMED (China) Limited have?

    As Jul 2024, HUTCHMED (China) Limited employs 1,988 workers.

  • When HUTCHMED (China) Limited went public?

    HUTCHMED (China) Limited is publicly traded company for more then 9 years since IPO on 16 Mar 2016.

  • What is HUTCHMED (China) Limited's official website?

    The official website for HUTCHMED (China) Limited is hutch-med.com.

  • How can i contact HUTCHMED (China) Limited?

    HUTCHMED (China) Limited can be reached via phone at +852 2128 1188.

HUTCHMED (China) Limited company profile:

HUTCHMED (China) Limited

hutch-med.com
Exchange:

NASDAQ

Full time employees:

1,970

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Cheung Kong Center
Central,

CIK: 0001648257
ISIN: US44842L1035
CUSIP: 44842L103